Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label 6‑month study of risperidone in adolescents with schizophrenia
2005-002979-33Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of risperidone in schizophrenia, sponsored by Janssen Pharmaceutical. Primary endpoint: Change in PANSS score. Started Sep 2005; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2005-002979-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002979-33.